Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells

Overview of attention for article published in Journal for Immunotherapy of Cancer, April 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (71st percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 13 X users

Readers on

mendeley: 109 Mendeley

Summary X

So far, Altmetric has seen 21 X posts from 13 X users, with an upper bound of 72,460 followers.

RT @NIHBrainTumor: Our colleagues @NCI_CCR_PedOnc are working to improve pediatric medulloblastoma treatment. In honor of #CCAM, check out…

23 Sep 2022

Reply Repost Favourite

RT @NIHBrainTumor: Our colleagues @NCI_CCR_PedOnc are working to improve pediatric medulloblastoma treatment. In honor of #CCAM, check out…

23 Sep 2022

Reply Repost Favourite

RT @NIHBrainTumor: Our colleagues @NCI_CCR_PedOnc are working to improve pediatric medulloblastoma treatment. In honor of #CCAM, check out…

23 Sep 2022

Reply Repost Favourite

Our colleagues @NCI_CCR_PedOnc are working to improve pediatric medulloblastoma treatment. In honor of #CCAM, check out this @jitcancer study by Anandani Nellan investigating the potential of 2nd generation HER2-CAR T cell therapies to treat this disease:

23 Sep 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 17 additional X posts.